Description
Trombital Pharmacodynamics
Reduces aggregation, platelet adhesion and thrombosis by inhibiting the synthesis of thromboxane A2 in platelets. The antiplatelet effect persists for
7 days after a single dose (more pronounced in men than in women).
Acetylsalicylic acid reduces mortality and the risk of myocardial infarction in unstable angina, is effective in the primary prevention of cardiovascular disease, especially myocardial infarction in men over 40 years, and in the secondary prevention of myocardial infarction.
Inhibits prothrombin synthesis in the liver and increases prothrombin time. Increases the fibrinolytic activity of blood plasma and reduces the concentration of vitamin K-dependent clotting factors (II, VII, IX, X). Increases the risk of hemorrhagic complications during surgical interventions, increases the risk of bleeding during anticoagulant therapy.
Acetylsalicylic acid in high doses also has anti-inflammatory, analgesic and antipyretic effects.
At high doses, acetylsalicylic acid stimulates excretion of uric acid (disrupts its reabsorption in the renal tubules).
Blockade of cyclooxygenase-1 in the gastric mucosa leads to inhibition of gastroprotective prostaglandins, which may cause mucosal ulceration and subsequent bleeding.
Magnesium hydroxide contained in Trombital protects the gastrointestinal mucosa from the effects of acetylsalicylic acid.
Indications
Primary prevention of cardiovascular diseases, such as thrombosis and acute heart failure, in the presence of risk factors (e.g. diabetes mellitus, hyperlipidemia, arterial hypertension, obesity, smoking, old age).
Prevention of recurrent myocardial infarction and blood vessel thrombosis.
Prevention of thromboembolism after surgical interventions on the vessels (coronary artery bypass grafting, percutaneous transluminal coronary angioplasty).
Unstable angina pectoris.
Contraindications
– Hypersensitivity to acetylsalicylic acid, excipients of the drug and other nonsteroidal anti-inflammatory drugs (NSAIDs);
– cerebral hemorrhage;
– susceptibility to bleeding (vitamin K deficiency, thrombocytopenia, hemorrhagic diathesis);
– gastrointestinal erosive and ulcerative lesions (in the acute phase);
– gastrointestinal bleeding;
– bronchial asthma induced by taking salicylates and other NSAIDs;
– complete or incomplete combination of bronchial asthma, recurrent nasal and paranasal sinus polyposis with intolerance to acetylsalicylic acid or other NSAIDs, including cyclooxygenase-2 inhibitors (including history);
– concomitant use of methotrexate at a dose of 15 mg per week or more;
– Pregnancy (I and III trimesters);
– Breast-feeding period;
– Glucose-6-phosphate dehydrogenase deficiency;
– severe renal insufficiency (creatinine clearance (CK) less than 30 ml/min);
– severe hepatic insufficiency (Child-Pugh grades B and C);
– chronic heart failure III and IV functional class according to NYHA classification;
– Children under 18 years of age.
Dosage and administration method.
- The drug is taken orally, once a day, with water. The tablet may be swallowed as a whole, chewed or crushed beforehand.
- Primary prevention of cardiovascular diseases, such as thrombosis and acute heart failure, in the presence of risk factors (e.g., diabetes mellitus, hyperlipidemia, arterial hypertension, obesity, smoking, advanced age): Take 2 tablets of the drug Trombital during the first day, then 1 tablet once a day.
- Prophylaxis of repeated myocardial infarction and thrombosis of blood vessels: take 1-2 tablets of Trombital once a day.
- Prevention of thromboembolism after surgical interventions on the vessels (coronary artery bypass grafting, percutaneous transluminal coronary angioplasty): 1-2 tablets of Trombital once a day.
- Unstable angina pectoris: 1-2 tablets of Trombital once a day.
- The drug is suitable for long-term use. Duration of treatment and dosage of Trombital is determined by physician.
- Use the drug only according to the indications, the method of administration and the dose stated in the instructions.
